Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results
Heinz Gisslinger(Medical University of Vienna), Christoph Klade(Intercell (Austria)), Michael Zoerer(AOP Orphan (Austria)), Margarete Stampfl‐Mattersberger(Donauspital), Ernst Forjan, Pavla Kadlecová, Barbara Grohmann-Izay(AOP Orphan (Austria)), Dominik Wolf(Universität Innsbruck), Ella Willenbacher(Innsbruck Medical University), Alexander Egle(Paracelsus Medical University), Richard Greil(Paracelsus Medical University), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Martin Schalling(Karolinska University Hospital), Bettina Gisslinger(Medical University of Vienna), Thomas Melchardt(Paracelsus Medical University), Maria‐Theresa Krauth(Medical University of Vienna), Victoria Empson(AOP Orphan (Austria)), Sonja Burgstaller(Klinikum Wels-Grieskirchen), Josef Thaler(Thrombolysis in Myocardial Infarction Study Group), Róbert Královics(Medical University of Vienna)
Cited by 18
Related Papers
A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders
|New England Journal of Medicine|2005|3.5k
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Bim is a suppressor of Myc-induced mouse B cell leukemia
|Proceedings of the National Academy of Sciences|2004|482
Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
|New England Journal of Medicine|1990|450